Ministry Of Health: Domestic Vaccine Types Of IdoVac Has Received A Circular Permit

Director General of Health at the Ministry of Health (Kemenkes), Lucia Rizka Andalusia. (ANTARA/Azmi Samsul Maarif)

JAKARTA - Director General of Health at the Ministry of Health (Kemenkes), Lucia Rizka Andalusia said, the IdoVac type of COVID-19 vaccine with a protein subunit platform developed by PT Bio Farma has now obtained a distribution permit to be used as a primary vaccine in stages one and two. "So for IndoVac made by PT Bio Farma, currently, it has received an Emergency Use Authorization (EUA) for primary vaccination doses one and two," said Lucia in Tangerang, Antara, Thursday, November 3. After experiencing a shortage of doses of the COVID-19 vaccine, his party continues to make efforts to produce and wait for permits related to the provision of the domestic vaccine. Saat ini setelah mendapat izin EUA dan certifikasi halal dari BPOM, maka vaksinasi pada masyarakat akan segera dilakukan untuk memperlancar proses vaksinasi kepada masyarakat. "And now IdoVac hopefully in the next one or two weeks, production can be used soon," he said. Meanwhile, for other domestic vaccines such as the InaVac type with an inactivated virus platform developed by Airlangga University team in collaboration with PT Biotis Pharmaceutical Indonesia will also soon obtain distribution permits from EUA and BPOM. "If the InaVac will immediately follow the distribution permit, maybe one to two days waiting for the announcement from BPOM," he said. Previously, the President Director of Pharmaceutical SOEs PT Bio Farma (Persero) Honesti Basyir stated his party's readiness to produce 20 million doses of IndoVac vaccine, for the initial stage. This amount can be increased to 40 million doses per year in 2023 by adding production facilities. Furthermore, production capacity can be increased again to 100 million doses per year by 2024, depending on the need and demand.